Literature DB >> 21615396

Adhesion molecules and high-sensitivity C-reactive protein levels in patients with sickle cell beta-thalassaemia.

Ino Kanavaki1, Periklis Makrythanasis, Christina Lazaropoulou, Antonis Kattamis, Revekka Tzanetea, Vassiliki Kalotychou, Ioannis Rombos, Ioannis Papassotiriou.   

Abstract

BACKGROUND AND AIM: The primary symptoms of sickle cell disease (SCD) arise from vaso-occlusive crises. The pathogenesis of these crises is complex phenomenon where endothelial activation and damage has a major role. Chronic inflammation also plays an important role in the pathophysiology of SCD. We aimed to investigate endothelial activation in Caucasian Greek patients with SCD by means of measuring adhesion molecules and markers of inflammation. SUBJECTS AND METHODS: Twenty-eight patients with SCD aged 5-63 years were included in the study. Most of the patients (23/28) were double heterozygotes for sickle cell/beta-thalassaemia, while five patients (5/28) were sickle cell homozygotes. Patients were treated with one/or more of hydroxyurea, therapeutic phlebotomies, blood transfusion or splenectomy. Twenty apparently healthy individuals matched for age and sex formed the control group. Measurements of soluble intercellular adhesion molecule-1, (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), P-selectin, E-selectin, soluble thrombomodulin (sTM) and high-sensitivity C-reactive protein (hs-CRP) levels were performed using immunoassays in both patients and healthy individuals.
RESULTS: We found that all endothelial adhesion molecules and hs-CRP were significantly increased (P < 0·001) in patients with SCD compared with controls, while sTM levels did not differ significantly (P > 0·05) and this increase was not influenced by the treatment.
CONCLUSION: Our findings demonstrate the high degree of endothelial activation and damage seen in sickle cell patients even in steady-state condition, as well as the important chronic inflammation underlying the pathophysiology of this widespread disease.
© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21615396     DOI: 10.1111/j.1365-2362.2011.02551.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Elevated D-dimer levels in African Americans with sickle cell trait.

Authors:  Rakhi P Naik; James G Wilson; Lynette Ekunwe; Stanford Mwasongwe; Qing Duan; Yun Li; Adolfo Correa; Alexander P Reiner
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

2.  Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.

Authors:  Carolyn Hoppe; Eufemia Jacob; Lori Styles; Frans Kuypers; Sandra Larkin; Elliott Vichinsky
Journal:  Br J Haematol       Date:  2017-03-28       Impact factor: 6.998

3.  Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.

Authors:  Jeffrey D Lebensburger; Thad Howard; Yunming Hu; Tamara I Pestina; Geli Gao; Melissa Johnson; Stanislav S Zakharenko; Russell E Ware; Elaine I Tuomanen; Derek A Persons; Jason W Rosch
Journal:  Blood       Date:  2011-11-30       Impact factor: 22.113

4.  Endothelial Activation Markers in Polytransfused Children with Beta Thalassemia: Study from a Tertiary Care Centre in India.

Authors:  Tushar Subhash Pallewar; Kusha Sharma; Sunita Sharma; Jagdish Chandra; Anita Nangia
Journal:  Indian J Hematol Blood Transfus       Date:  2021-07-27       Impact factor: 0.900

Review 5.  Hypoxia and inflammation in children with sickle cell disease: implications for hippocampal functioning and episodic memory.

Authors:  Mary Iampietro; Tania Giovannetti; Reem Tarazi
Journal:  Neuropsychol Rev       Date:  2014-04-18       Impact factor: 7.444

6.  Inflammation in sickle cell disease.

Authors:  Nicola Conran; John D Belcher
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.